1 no longer available, 1 recruiting, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
Follow Devalingam Mahalingam: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Hepatocellular Carcinoma, Cirrhosis | Phase 1 / Phase 2 | Recruiting | Devalingam Mahalingam | 59 | 2026-03-30 | 2026-10-23 |
| Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer Sotorasib, Liposomal Irinotecan (nal-IRI), 5 Fluorouracil (5FU) - Pancreatic Cancer, Unresectable Pancreatic Cancer | Phase 1 / Phase 2 | Withdrawn | Devalingam Mahalingam | 2022-09-13 | 2023-05-11 | |
| Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma G-202 - Hepatocellular Carcinoma | No longer available | Devalingam Mahalingam | 2014-03-10 |
Carcinoma, Hepatocellular (2) · Fibrosis (1) · Pancreatic Neoplasms (1)
Albumin-Bound Paclitaxel (1) · Fluorouracil (1) · Gemcitabine (1) · Leucovorin (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · Taxes (1) · irinotecan sucrosofate (1) · sotorasib (1)
United States (2)
P30CA060553 (1)